Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits

dc.contributor.author	Martin, NK	en_US
dc.contributor.author	Vickerman, P	en_US
dc.contributor.author	Dore, GJ	en_US
dc.contributor.author	Grebely, J	en_US
dc.contributor.author	Foster, GR	en_US
dc.contributor.author	Miners, A	en_US
dc.contributor.author	Hutchinson, S	en_US
dc.contributor.author	Goldberg, DJ	en_US
dc.contributor.author	Martin, TC	en_US
dc.date.accessioned	2015-03-25T14:44:46Z
dc.date.issued	2014	en_US
dc.identifier.issn	0270-9139	en_US
dc.identifier.uri	http://qmro.qmul.ac.uk/xmlui/handle/123456789/7003
dc.format.extent	1042A - 1042A	en_US
dc.title	Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits	en_US
dc.type	Conference Proceeding
pubs.author-url	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804314&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a	en_US
pubs.notes	Not known	en_US
pubs.publication-status	Published	en_US
pubs.volume	60	en_US

Files in this item

Files	Size	Format	View
There are no files associated with this item.